Immunoglobulins in Defense, Pathogenesis, and Therapy of Fungal Diseases  by Casadevall, Arturo & Pirofski, Liise-anne
Cell Host & Microbe
ReviewImmunoglobulins in Defense, Pathogenesis,
and Therapy of Fungal DiseasesArturo Casadevall1,* and Liise-anne Pirofski1
1Departments of Microbiology and Immunology and Medicine, Division of Infectious Diseases, Albert Einstein College of Medicine and
Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY 10461, USA
*Correspondence: arturo.casadevall@einstein.yu.edu
DOI 10.1016/j.chom.2012.04.004
Only two decades ago antibodies to fungi were thought to have little or no role in protection against fungal
diseases. However, subsequent research has provided convincing evidence that certain antibodies can
modify the course of fungal infection to the benefit or detriment of the host. Hybridoma technology was
the breakthrough that enabled the characterization of antibodies to fungi, illuminating some of the require-
ments for antibody efficacy. As discussed in this review, fungal-specific antibodies mediate protection
through direct actions on fungal cells and through classical mechanisms such as phagocytosis and comple-
ment activation. Although mechanisms of antibody-mediated protection are often species-specific,
numerous fungal antigens can be targeted to generate vaccines and therapeutic immunoglobulins. Further-
more, the study of antibody function against medically important fungi has provided fresh immunological
insights into the complexity of humoral immunity that are likely to apply to other pathogens.The past two decades have been momentous in advancing our
understanding of the role of antibody-mediated immunity (AMI)
in host defense against fungi, and they have brought about
a paradigm shift in our thinking on this question. Prior to the
1990s, AMI was considered to be irrelevant in host defense
against fungi (for review, see Casadevall, 1995), as the experi-
mental methods that were in use at the time were not able to
consistently establish a role for AMI. These methods, including
passive transfer of immune sera to naive hosts and correlating
the presence of serum antibody with immunity to fungal disease,
often yielded negative results, and there was a lack of associa-
tion between invasive fungal diseases and known antibody
defects in humans. By contrast, ample evidence that cell-medi-
ated immunity (CMI) was essential for resistance to fungal
diseases resulted in CMI being viewed as the arm of the immune
system responsible for host defense against fungi. In a prior
essay we described the practice of characterizing microbes by
whether host defense against them was dependent on AMI or
CMI as the ‘‘great immunological catastrophe of the 20th
century’’ because this subdivision limited research on microbial
pathogenesis and immunity to a single arm of the immune
system, ignoring the other(s) (Casadevall and Pirofski, 2011).
However, for fungi the situation changed rapidly after Dromer
and her colleagues showed that a monoclonal antibody (mAb)
to Cryptococcus neoformans was protective against lethal cryp-
tococcal infection in mice (Dromer et al., 1987b). At about the
same, time a protective mAb was reported against the fungus
Pneumocistis carinii, although this organism was thought to be
a protozoan at the time (Gigliotti and Hughes, 1988). Subse-
quently, protective mAbs have been successfully generated
against five medically important fungi (Table 1). The fact that
certain antigens recognized by some of the aforementioned
mAbs are expressed by different fungi has raised optimism
that universal antifungal vaccines that protect via AMI could be
generated.The breakthrough that made the identification of protective
antibodies to fungi possible was themAb technology. In contrast
to polyclonal sera, mAbs provided defined reagents that recog-
nized a single antigenic determinant and yielded consistent and
reproducible results. Furthermore, and importantly, studies with
mAbs led to the discovery that depending on their specificity and
isotype, mAbs to fungi can mediate three different effects
in being protective, nonprotective (indifferent), or disease-
enhancing. The observed disease-enhancing properties of
mAbs provided an explanation for historical difficulties in estab-
lishing a role for AMI with polyclonal preparations, as these intrin-
sically heterogeneous reagents were likely to contain a variety of
antibodies in varying proportions with each of the foregoing
activities. Hence, studies with mAbs established definitively
that protective immunoglobulins to fungi can be produced and
that the historical inability to establish a role for AMI in protection
against fungi was most likely a function of the heterogeneous
preparations used, rather than a fundamental limitation of AMI.
Given the rising tide of mycotic diseases, understanding the
role of AMI in host defense against fungi is particularly important.
Mycotic diseases have increased significantly as a result of use
of antibacterial agents, which alter the host associate microbiota
and immunosuppressive therapies, which induce impaired
immunity. Most invasive fungal infections occur in patients with
impaired immunity due to one of the interventions noted above
or acquired immunodeficiency, such as HIV/AIDS. Given that
immunosuppression enhances fungal pathogenesis, it is not
surprising that despite ample in vitro activity, antifungal drugs
often cannot eradicate the fungal burden in patients with
impaired immunity. As such, fungal diseases are difficult to treat,
have high morbidity andmortality, and often result in latency that
can reactivate in the setting of immune suppression. Conse-
quently, there is a great need to develop new approaches to treat
and prevent fungal diseases. Immunoglobulins offer a very
attractive approach. Vaccines that elicit AMI have a long trackCell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc. 447
Table 1. Fungal Antigens that Have Been Shown to Elicit Protective Antibodies
Fungus Antigen Reference
Aspergillus fumigatus Beta-1,3 glucan (Torosantucci et al., 2009)
Cell wall glycoprotein (Chaturvedi et al., 2005)
Candida albicans Secreted aspartyl proteinase2 (Sandini et al., 2011)
Beta-1,3 glucan (Torosantucci et al., 2009; Torosantucci et al., 2005)
Mp58 mannoprotein (Viudes et al., 2004)
Beta-(1-2)-linked mannotriose (Han et al., 1997)
Heat-shock protein 90 (Matthews et al., 1991)
Als3 (Brena et al., 2007)
Phosphoglycerate kinase (Calcedo et al., 2011)
Fructose bisphophate aldolase (Calcedo et al., 2011)
Cryptococcus neoformans Beta-1,3 glucan (Torosantucci et al., 2009)
Glucuronoxylomannan (GXM) (Dromer et al., 1987a; Sanford et al., 1990; Mukherjee et al., 1992;
Fleuridor et al., 1998; Beenhouwer et al., 2007)
Glucosylceramide (Rodrigues et al., 2000)
Melanin (Rosas et al., 2001)
Histoplasma capsulatum Heat shock protein 60 (Guimara˜es et al., 2009b)
Histone-like protein (Nosanchuk et al., 2003)
70 kDa cell surface protein (Lopes et al., 2010a)
Paracoccidioides brasiliensis gp43 (Buissa-Filho et al., 2008)
Melanin (da Silva et al., 2006)
Pneumocystis species Glycoprotein A (Gigliotti et al., 1996)
Major surface glycoprotein (Smulian et al., 2000)
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served as inaugural antimicrobial agents in the preantibiotic era,
immunoglobulins are increasingly being considered as potential
therapies for a variety of microbes (Casadevall et al., 2004).
Consequently, there is now great interest in the development
of vaccines and therapeutic antibodies for fungi, but progress
in this area must contend with the complexity of AMI for this
group of pathogens.
In this review, we discuss the tremendous progress that has
beenmade in the field of AMI to fungal pathogens, with emphasis
on how information learned with the fungi has informed immu-
nology on basic mechanisms of antibody action.
Challenges Posed by Fungal Pathogens
In containing fungi, the immune system faces unique challenges
unlike those posed by bacteria and viruses. Many fungal patho-
gens exhibit dimorphism, a characteristic that enables them to
exist as hyphae or yeast cells, with each form having a distinct
surface and antigenic composition. Fungal cells are surrounded
and protected by a cell wall, which is a structure composed of
crosslinked polysaccharides including chitin and other compo-
nents. An important functional effect of the fungal cell wall is
to inhibit the ability of complement to damage fungal cell
membranes, even though complement activation can elicit an
antifungal inflammatory response. Hence, antibody-dependent
complement activation does not result in direct damage to fungal
cells. However, there are now several examples of mAbs that
bind to cell wall components and inhibit replication (Table 2).
Although the mechanism by which mAbs bind and affect the
fungal cell wall is not understood, it is possible that the complex448 Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc.nature of the cell wall requires a tightly regulatedmetabolism that
is disrupted by the attachment of immunoglobulin molecules.
Fungal cells are notorious for producing secondary metabolites
with deleterious effects. For example, mannitol production can
interfere with host oxidative defenses, and mycotoxins such as
gliotoxin are toxic to immune effector cells. Adding to the difficul-
ties encountered by the immune system, fungal pathogens can
exhibit antigenic variation. The phenomenon of fungal dimor-
phism means that many pathogenic fungi can exist in two
different forms in the host, each of which is antigenically dis-
tinct. For C. neoformans, antigenic diversity stems from the
capsular polysaccharide, and it is estimated that each cell is
antigenically unique owing to combinatorial diversity of the poly-
saccharide capsule (McFadden et al., 2007). In addition, the
C. neoformans capsule is antiphagocytic and capable of
quenching free radicals produced by host immune cell oxidative
burst (Zaragoza et al., 2008). Capsular polysaccharide released
by C. neoformans cells in tissue interferes with the inflammatory
response and inhibits recruitment and the function of effector
cells that are empowered by specific antibodies. Fungi are also
capable of forming very large structures in tissue. Aspergillus
species form dense collections of hyphae in tissue that induce
surrounding tissue necrosis, and C. neoformans and Cocci-
dioides immitis can each generate enormous structures in tissue
known as giant or titan cells and spherules, respectively.
C. neoformans giant cells are far larger than macrophages,
precluding phagocytosis and posing a formidable problem for
host defenses (Zaragoza et al., 2010; Okagaki et al., 2010).
Although fungi exert a multitude of effects that thwart host
defense, these very effects provide rational targets for AMI as
Table 2. Mechanisms of Antibody-Mediated Protection against Fungi
Mode Mechanism Comment References
Indirect Phagocytosis This mechanism may be particularly
important for fungi that actively resist
phagocytosis, such as C. neoformans.
However, phagocytosis may not be
sufficient as a host-protective mechanism
since many fungi can survive intracellularly.
(Schlageter and Kozel, 1990)
Complement activation Appears to be critical for IgM but may be
dispensable for IgG
(Shapiro et al., 2002; Han et al., 2001)
Antibody-directed cellular cytotoxicity Best example is the requirement for specific
antibody in NK cell-mediated antifungal
effects against C. neoformans
(Nabavi and Murphy, 1986)
Phagosome activation mAbs to H. capsulatum promote
phagosome maturation and thus interfere
with fungal mechanisms of intracellular
survival
(Shi et al., 2008)
Modulation of the inflammatory response mAbs toC. neoformansmediate changes in
inflammatory responses that are associated
with better control of infection in tissue
(Feldmesser et al., 2002; Feldmesser and
Casadevall, 1997)
Direct Inhibition of biofilm formation An in vitro observation for C. neoformans
that could reflect the ability of specific
antibody to the capsule to interfere with
polysaccharide release
(Martinez and Casadevall, 2005)
Inhibition of polysaccharide release Given the many deleterious effects
associated with polysaccharide in tissue,
the ability of antibody to reduce capsule
shedding from C. neoformans could
translate into more effective immune
responses.
(Martinez et al., 2004)
Inhibition of replication and cytotoxicity The mechanism is unknown, but antibodies
that bind cell wall components can inhibit
replication and/or trigger cell death.
(Brena et al., 2007; Moragues et al., 2003;
Magliani et al., 2005; Rosas et al., 2001)
Interference with dimorphic changes Some mAbs to C. albicans interfere with
germ tube formation.
(Moragues et al., 2003)
Alterations in gene expression Antibody binding to the C. neoformans
capsule triggers changes in gene
expression that can make the fungus more
vulnerable to antifungal agents.
(McClelland et al., 2010)
Iron starvation Iron starvation appears to be the
mechanism by which a mAb is cytotoxic
and interferes with morphogenesis.
(Brena et al., 2011)
Mimicking killer toxin Anti-idiotypic antibodies to yeast killer toxin
mimic the structure of killer toxin and are
active against many fungal species.
(Magliani et al., 2005)
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capsular polysaccharides can serve to inhibit their deleterious
effects.
Mechanisms of AMI against Fungi
Most current knowledge about mechanisms of AMI against fungi
comes from studies with C. neoformans and C. albicans, which
are among the most common and most studied human patho-
genic fungi. Historically, mechanisms of AMI, or classical mech-
anisms, were held to include opsonization, complement activa-
tion, viral and toxin neutralization, and antibody-dependent
cellular cytotoxicity (ADCC) (Casadevall and Pirofski, 2011).
Among thesemechanisms, viral neutralization is not immediatelyrelevant, although some of the mechanisms by which viral
neutralization ismediated could have parallels in fungal-antibody
interactions. Each of the other classical functions could have
a role in host defense against fungi. For example, opsonization
is very important for host defense against C. neoformans, as
the polysaccharide capsule abrogates phagocytosis and com-
plement is not an effective opsonin for some strains (Zaragoza
et al., 2003). Whether ingestion is an effective mechanism for
controlling C. neoformans depends on the activation state of
the cell and the immunological state of the host, as this fungus
has the capacity for intracellular replication and can even escape
the phagocytic cell by nonlytic exocytosis. In fact, intracellular
replication can be faster than extracellular growth. In animalCell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc. 449
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essential for the function of specific IgM, butmay be dispensable
for IgG (Shapiro et al., 2002). In theory, toxin neutralization could
contribute to host defense against fungi that produce myco-
toxins, but this has not been demonstrated to date. Fc
receptor-dependent ADCC can mediate protection against
C. albicans (van Spriel et al., 2001), and antibody-dependent
NK cell-mediated activity against C. neoformans has been dem-
onstrated (Miller et al., 1990; Nabavi andMurphy, 1986). Another
antibody-mediated antifungal mechanism is exemplified by
the ability of anti-idiotypic antibodies mimicking killer toxin to
directly damage fungal cells by interacting with the killer toxin
receptor (Magliani et al., 2005).
In addition to the aforementioned classical mechanisms of
AMI, new mechanisms of antibody action against fungi have
been identified (Table 2). One suchmechanism is that antibodies
to certain fungal determinants are able to mediate direct anti-
fungal effects without the need for host cells. For example,
a mAb to Candida albicans mannoprotein has been shown to
mediate three different activities: inhibition of adherence, inhibi-
tion of germination, and direct candidacidal activity (Moragues
et al., 2003), with the direct effects involving antibody-mediated
iron starvation (Brena et al., 2011). In addition, antibody-medi-
ated inhibition of an aspartyl proteinase has been associated
with protection against vaginal candidiasis (De Bernardis et al.,
1997), and antibodies to 1,2 b mannotriose (Xin et al., 2008)
and cell wall protein-derived peptides protect against dissemi-
nated candidiasis in mice (Xin and Cutler, 2011). Antibodies to
cell wall b-glucans have been shown to interfere with adherence
and cell wall remodeling (Torosantucci et al., 2005, 2009) and
have demonstrated the capacity for direct antifungal activity
via growth inhibition of C. albicans as well as Cryptococcus neo-
formans (Torosantucci et al., 2009). As exemplified by the direct
antifungal and growth-inhibitory capacity of b-glucan antibodies,
and the ability of AMI elicited by a cell wall b-glucan-based
vaccine to protect against multiple fungi (Torosantucci et al.,
2005), studies with mAbs have provided proof of principle that
the development of universal fungal therapies and vaccines
that provide AMI upon binding conserved fungal b-glucans could
be possible.
For Cryptococcus neoformans, studies with mAbs have
demonstrated several direct antibody-mediated effects, in-
cluding interference with capsular polysaccharide release and
biofilm formation. However, there is also considerable evidence
that specific antibody to theC. neoformans capsule canmediate
protection indirectly. These indirect mechanisms of protection
alter the inflammatory response and depend on collaboration
with effector cells and/or CMI. In fact, the primary mechanism
of antibody-mediated protection against C. neoformans is
most likely via modification of the inflammatory response in
a manner that enhances fungal clearance and minimizes in-
flammatory damage to tissue (reviewed in Casadevall and Pirof-
ski, 2003). Specific antibody can also alter the nature of
C. neoformans-macrophage interaction, as exemplified by
data showing that antibody-opsonized C. neoformans exits
macrophages as biofilm-like microcolonies, whereas planktonic
cells exit after complement opsonization (Alvarez et al., 2008). A
similar mechanism may underlie antibody-mediated protection
against murine histoplasmosis, as antibody administration was450 Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc.associated with reduced inflammatory damage (Guimara˜es
et al., 2009a). The mechanism for these effects may be a result
of antibody-mediated changes in the H. capsulatum-macro-
phage interaction, as antibody-dependent opsonization en-
hanced phagosome activation, acidification, and maturation,
which can result in more efficient T cell activation and more
effective CMI (Shi et al., 2008).
AMI in Natural Resistance to Fungi
Cryptococcus neoformans
Despite overwhelming evidence that individual mAbs canmodify
the course of fungal infection to the benefit of the host (see Table
1), a definitive role for natural AMI in host defense against fungi
has been difficult to establish. Historically, the lack of (1) a clear
association between known B cell defects and a predisposition
to fungal disease and (2) a clear relationship between serum anti-
body to fungal antigens and resistance to fungi led most to
conclude that AMI has no role in host defense against fungi in
patients. However, this conclusion was flawed, as it was based
on negative (a lack of) association. Part of the difficulty in estab-
lishing a relationship between antibody and resistance to fungal
disease is that most immunologically intact individuals produce
many antibodies that bind fungal antigens, entities to which
they are constantly exposed. In fact, immunologically intact indi-
viduals are at very low risk of ever developing disease. Since
antibodies to major fungal pathogens, such as Cryptococcus
neoformans and C. albicans, are commonly present in individ-
uals who have no history of disease as well as many who do,
the presence of serum antibody does not discriminate those
who are immune from those who are susceptible (Casadevall
and Pirofski, 2007). However, the same information could be in-
terpreted differently. For example, one could argue that the high
prevalence of serum antibodies to fungal determinants in normal
individuals together with the very low incidence of fungal disease
in this group is consistent with a protective role for AMI against
fungi. Further, some of these observations might be reconciled
if AMI is beneficial when present but not necessarily required.
Nonetheless, serum antibody can identify individuals who are
susceptible to reactivation-associated disease. For example,
as serological evidence against C. neoformans is detectable
early in childhood (Goldman et al., 2001; Abadi and Pirofski,
1999), the presence of specific antibody has been cited to
suggest that solid organ transplantation-associated cryptococ-
cosis stems from reactivation of latent infection in patients with
prior infection (Saha et al., 2007). However, such data also imply
that pre-existing antibody did not prevent reactivation. This is not
surprising in view of the critical importance of CMI in resistance
to C. neoformans and ample evidence that natural resistance to
disease requires both AMI and CMI (Rivera et al., 2005; Yuan
et al., 1997; Beenhouwer et al., 2001). Nonetheless, crypto-
coccal disease has been reported in patients with B cell defects,
including X-linked hyperIgM (Winkelstein et al., 2003; de Go´rgo-
las et al., 2005), a disorder with B, in addition to T, cell defects
(Agematsu et al., 1998), and hypogammaglobulinemia (Gupta
et al., 1987; Wahab et al., 1995; Neto et al., 2000). In addition,
IgG2 deficiency was identified in an otherwise normal individual
who developed meningitis with C. gattii (Marr et al., 2012), and
compared to those without HIV/AIDS, adults and children with
HIV/AIDS have lower titers of specific IgG2, the cryptococcal
Cell Host & Microbe
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and Pirofski, 1999; Deshaw and Pirofski, 1995). IgG2 is the
predominant IgG subclass to polysaccharide antigens in hu-
mans (Pirofski, 2001).
The most common immune deficiency among patients with
cryptococcal disease is HIV, and HIV-associated B cell defects
have been linked to cryptococcal disease susceptibility. HIV-
infected participants in the Multicenter AIDS Cohort Study
(MACS) who developed cryptococcosis had lower levels of
serum antibody-expressing VH3 genes and IgM to GXM than
those who did not. Similar observations have been reported
with HIV-infected individuals in other cohorts (Deshaw and Pir-
ofski, 1995; Fleuridor et al., 1999; Subramaniam et al., 2009).
The loss of B cells and serum antibody-expressing VH3 deple-
tion is a well-documented HIV-associated defect (Berberian
et al., 1994, 1993). Hence, as human antibodies to GXM use
VH3 genes (Fleuridor et al., 1998, 1999; Pirofski et al., 1995),
HIV-associated depletion of VH3-expressing B cells could
translate into a hole in the GXM-reactive repertoire. Another
HIV-associated deficit that has been linked to cryptococcal
disease susceptibility is IgM memory B cell depletion. Identified
as one of the original HIV-associated B cell deficiencies (Lane
et al., 1983), IgM memory B cell depletion remains a complica-
tion of HIV/AIDS even in the HAART era (Moir and Fauci, 2009)
and has been linked to HIV-associated cryptococcal disease
susceptibility (Subramaniam et al., 2009). IgM memory B cells
are the source of natural IgM that has the capacity to bind
conserved microbial carbohydrates (Baumgarth et al., 2005;
Griffin et al., 2011). Hence, the lower levels of IgM to GXM
that have been reported in the sera of patients with HIV/AIDS
(Deshaw and Pirofski, 1995; Fleuridor et al., 1999; Subramaniam
et al., 2009), as well as pretransplant sera of patients who devel-
oped cryptococcal disease after solid organ transplantation
(Jalali et al., 2006), could contribute to the development of cryp-
tococcal disease in addition to being a possible sentinel for IgM
memory B cell deficiency.
In contrast to the uncertain relationship between AMI and
resistance to fungi that has arisen from serological studies in
humans, investigations in experimental animals provide strong
evidence for a contribution of natural AMI to host defense against
fungi. An early study demonstrated increased susceptibility to
C. neoformans in mice with X-linked immunodeficiency (Marquis
et al., 1985). More recently, B cell-deficient (Rivera et al., 2005)
and IgM-deficient (sIgM/) (Subramaniam et al., 2010b) mice
have each been shown to be more susceptible to pulmonary
infection with C. neoformans. Interestingly, when sIgM/ mice
were infected intraperitoneally, they were protected against
C. neoformans (Subramaniam et al., 2010a). Seemingly paradox-
ically, this finding underscores the complexity of AMI to fungi and
highlights that it is often tissue specific. Hence, while secreted
IgM appears to be crucial for granuloma formation and prevent-
ing dissemination of C. neoformans from the lungs (Subrama-
niam et al., 2010b), an excess of B-1 B cells and IgG2 (which is
characteristic of sIgM/ mice) appears to mediate protection
in the peritoneal cavity despite the absence of IgM, most likely
by enhancing the fungicidal activity of macrophages (Subrama-
niam et al., 2010a). Hence, IgM and B cells exhibit different,
tissue-specific roles in resistance to cryptococccal dissemina-
tion and death in mice.Candida albicans
Observational studies in patients with candidiasis led to the iden-
tification of antibodies to an antigen, subsequently recognized
as hsp90, that were associated with survival (Matthews et al.,
1991). This observation spawned work that led to the develop-
ment of an antibody-based fragment for treatment of fungal
disease, Mycograb (Pachl et al., 2006). Although Mycograb
enhanced the activity of antifungal agents against C. albicans
inmice (Matthews et al., 2003) and improved outcome in invasive
candidiasis in combination with liposomal amphotericin in a
randomized, multicenter clinical trial (Pachl et al., 2006), its
clinical development has been discontinued (see below). The
complex states of human C. albicans infection, from commen-
salism to disease, present a unique challenge in efforts to char-
acterize the role of AMI in resistance to disease and harness the
potential of antibody-based therapy in patients. Studies in mice
have been more straightforward, but have yielded different
results depending on the fungal strain, route of infection, and
animal model. B cell-deficient mice succumbed more rapidly
than wild-type mice when infected with filamentous forms of
C. albicans (Saville et al., 2008), and mice depleted of B cells
were more susceptible (Sinha et al., 1987). In another model, B
cell-deficient mice survived primary infection with C. albicans
and Aspergillus fumigatus (Montagnoli et al., 2003), but
C. albicans-infected mice did not survive a secondary challenge
due to a failure of immunoregulation, rather than fungal clear-
ance. Normal mouse serum reversed the effects and reconsti-
tuted a survival phenotype (Montagnoli et al., 2003). This study
reiterated findings from the aforementioned C. neoformans
models in which AMI conferred protection via immunoregulation
and control of inflammation.
Other Fungal Pathogens
In contrast toC. albicans andC. neoformans, B cell depletion did
not alter mortality in mice with primary H. capsulatum infection
(Allendo¨rfer et al., 1999), however, B cells protected against
fungal reactivation in immune mice (Allen and Deepe, 2006).
B cells have also been shown to have an immunoregulatory
role in immunity to Pneumocystis in mice (Lund et al., 2006).
B-1 B cells and natural IgM to conserved b-glucan determinants
secreted by B-1 B cells were shown to enhance innate immunity
to Pneumocystis via dendritic cell priming (Rapaka et al., 2010),
providing another instance of IgM-mediated antifungal immunity
as demonstrated forC. neoformans (Subramaniam et al., 2010b).
Further evidence for AMI-mediated resistance to Pneumocystis
is found in a report that simian immunodeficiency virus-infected
macaques with IgG to a Pneumocystis protein (KEX-1) were
more resistant to Pneumocystis colonization and lung disease
than macaques without IgG (Rapaka et al., 2010). In contrast
to their protective role in Pneumocystis and intraperitoneal infec-
tion with C. neoformans (as IgM-deficient mice have elevated
levels of B-1 B cells; Subramaniam et al., 2010a), B-1 B cells
had a detrimental effect in pulmonary P. brasilienses infection
in mice, albeit in a different mouse model in which disease
enhancement was attributed to B-1 B cell production of IL-10
and impairment of phagocytosis (Popi et al., 2008).
AMI has been shown to be important for the generation of long
lasting immunity to C. albicans and A. fumigatus (Montagnoli
et al., 2003) and, as noted above, for maintenance of immunity
to H. capsulatum (Allen and Deepe, 2006). In addition to IgM,Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc. 451
Figure 1. Proposed Mechanisms of
Antibody Action against Fungi
(A–C) The proposed mechanisms of antibody
action against fungi can be considered under three
general categories involving (A) direct inhibition of
growth, (B) immunomodulation and potentiation of
innate immunemechanisms, and (C) neutralization
of the untoward effects of fungal products on host
tissues.
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tetraspanin protein (CD37)-deficient mice, which have 15-fold
higher levels of IgA, were less susceptible than wild-type mice,
and sera from CD37-deficient mice enhanced resistance of
wild-type mice (van Spriel et al., 2009). The major mechanisms
by which AMI contributes to host defense against fungi are
shown in Figure 1.
Contribution of AMI in Pathogenesis and Susceptibility
to Fungi
Given that AMI is a critical arm of the immune response, and
fungi cause disease in the setting of immunodeficiency and
excessive immune responses, i.e., at both ends of the
damage-response spectrum (Casadevall and Pirofski, 2011), it
is likely that some antibody responses can be deleterious. For
example, IgE to fungal antigens has been implicated in the devel-
opment of allergic pulmonary aspergillosis, fungal sinusitis, and
forms of asthma that are caused by C. neoformans (Goldman
et al., 2006). However, evidence that AMI contributes to the path-
ogenesis of and susceptibility to invasive fungal disease is indi-
rect at best, with most data coming from experimental animal
models. The capacity of AMI to enhance fungal disease was
discovered with the identification of disease-enhancing mAbs
that shortened survival when they were administered to
C. neoformans-infected mice (Nussbaum et al., 1996). However,
enhancement was limited to certain mouse strains and the same
mAb that was enhancing in one strain was protective in another
(Rivera and Casadevall, 2005). Recently, disease-enhancing
monoclonal antibodies have also been reported for Scedospo-
rium apiospermum, a soil fungus that causes invasive and nonin-
vasive infection in susceptible individuals (Lopes et al., 2010b). A
comparison of Balb/c and C.B-17 mice, which differ in their
capacity to clear pulmonary C. neoformans infection revealed
that human immunoglobulin locus genes were associated with
slower clearance in Balb/c mice (Lovchik et al., 1999). The en-
hanced susceptibility of Balb/c mice to cryptococcosis has been
associated with significantly higher levels of C. neoformans-
specific IgM, IgG1, IgG2a, and IgG3 and Th2 polarization of
the pulmonary inflammatory response (Lovchik et al., 1999). In
contrast, susceptible C57BL/6 mice had higher levels of IgG2b
after intraperitoneal infection with C. neoformans (Subramaniam
et al., 2010a). IgG2b has been associated with inferior opsonic
activity in vitro (Sanford et al., 1990) for some mAbs, but not
others (Yuan et al., 1998). Methamphetamine administration
increased susceptibility toH. capsulatum inmice, a phenomenon
associated with pleitropic effects on the immune system452 Cell Host & Microbe 11, May 17, 2012 ª2012 Elsevier Inc.including alterations in antibody re-
sponses (Martinez et al., 2009). For
C. albicans, a comparison of genetically
resistant and susceptible mouse strainsrevealed qualitative and quantitative differences in the antibody
response, but such results do not infer causality (Costantino
et al., 1995). Similarly, differences in the susceptibility of mice
to Paracoccidioides brasiliensis correlated with differences in
the isotype composition such that resistant and susceptible
strains produced IgG2a and IgG2b isotypes, respectively
(Kashino et al., 2000). However, we note that these differences
occurred in a background of many immunological differences,
making the degree to which AMI contributed to disease patho-
genesis unclear. On the other hand, specific IgG was associated
with resistance to colonization and lung disease after exposure
to Pneumocystis in macaques (Kling et al., 2010), and IgM-
deficient mice that exhibited resistance to intraperitoneal
infection with C. neoformans had higher levels of IgG2a than
susceptible mice (Subramaniam et al., 2010a). However, it
should be noted that a given antibody type can be the byproduct
of a Th2-polarized response, thus being only a small part of
a complex B and T cell response. Thus, links between the pres-
ence of antibody and an outcome of fungal infection are associ-
ations that do not imply or establish a causal relationship
between AMI and an outcome of fungal infection. Nonetheless,
immune responses to fungi are considered notorious for eliciting
antibodies that are not considered to be protective as exempli-
fied for antibodies to Candida (Farah and Ashman, 2005) and
Coccidiodes species (Cole et al., 2004), and the phenomenon
may be more widespread.
Efficacy of Induced AMI against Fungi in Prophylaxis
and Therapy
Given the high mortality, chronicity, and refractoriness of fungal
diseases to therapy, there is currently considerable interest in the
use of antibodies to prevent disease and as adjuncts to standard
antifungal therapy. AMI can be induced actively and passively.
The efficacy of passive antibody administration is convincingly
established against various fungi (Table 1), and several vaccine
formulations have also been shown to mediate protection by
eliciting protective antibody responses in mice (Table 3). One
concern in inducing AMI is that prozone-like effects have been
demonstrated against fungi, in which loss of protective efficacy
is apparent at high relative to lower antibody concentrations
(Taborda et al., 2003). Hence, it is conceivable that highly immu-
nogenic vaccines could fail if they elicit exuberant antibody
responses with high antibody titers. Nevertheless, the experi-
ence with many effective vaccines against bacterial and viral
pathogens provides strong encouragement that effective anti-
fungal vaccines can be developed. A vaccine against recurrent
Table 3. Experimental Vaccines that Protect through AMI
Vaccine Target Mechanism Reference
Glucuronoxylomannan-tetanus
toxoid conjugate
C. neoformans Vaccine elicits antibody responses
to the polysaccharide capsule
(Devi, 1996)
Peptide mimotope C. neoformans Peptide elicits antibody responses
that react with the capsule
(Fleuridor et al., 2001)
Synthetic glycopeptide C. albicans Antibodies to cell wall beta mannans (Xin et al., 2008)
Mannan-protein conjugate C. albicans Antibodies to cell wall beta mannans (Han et al., 1999)
Beta-glucan conjugate C. albicans, A. fumigatus,
C. neoformans
Antibodies to cell wall beta glucans (Torosantucci et al., 2005;
Torosantucci et al., 2009)
Recombinant and truncated
aspartic protease
C. albicans Protease neutralization (Sandini et al., 2011)
Glycan-peptide conjugates C. albicans Antibodies to cell wall (Xin and Cutler, 2011)
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Reviewvulvovaginal candidiasis known as PEV7 which expresses re-
combinant aspartyl protease on virosomes produced by Pevion
Biotech AG (Bern, Switzerland) is currently in clinical evaluation.
A murine IgG1 mAb for C. neoformans that was studied in a clin-
ical trial was found to be safe and to reduce serum GXM when
used at high doses (Larsen et al., 2005). Further clinical develop-
ment of this mAb has been hampered by economic issues re-
sulting from the high costs of drug development for a disease
of relatively low prevalence. A recombinant antibody fragment
toC. albicansHSP90 (efungumab,Mycograb) showed promising
efficacy in clinical trials (Pachl et al., 2006), but subsequent
development of this immunoglobulin derivative has been ham-
pered by production difficulties and was abandoned by Novartis
(http://www.novartis.com/newsroom/media-releases/en/2010/
1449020.shtml). Despite the absence of licensed products that
prevent or treat fungal diseases based on AMI, the fact that anti-
bodies and vaccines have been tested clinically is a measure of
the interest in and acceptance of the concept that the pursuit of
AMI for fungal diseases warrants consideration in clinical medi-
cine. Furthermore, newer types of antibody preparations are
on the horizon. For example, the efficacy of antibody can be
enhanced by linking it to a radioactive isotope, since this con-
verts the antibody in a fungicidal molecule (Dadachova et al.,
2003) irrespective of its natural biological function. In fact, by
targeting antigens shared across fungal species, it may be
possible to develop broad spectrum radioimmunotherapy for
fungal diseases (Bryan et al., 2011). This could be an attractive
option for developing new antifungal strategies against the
devastating mold infections that occur in severely immunocom-
prised individuals.
Summary
In a little more than two decades the field of AMI to medically
important fungi has gone from being a remote backwater of
scientific study to a vibrant field that is now generating promising
vaccines and therapeutic immunoglobulins while making major
contributions to basic immunology and microbial pathogenesis.
In fact, we have recently proposed a new synthesis for AMI
based largely on discoveries made with antibodies to fungi
(Casadevall and Pirofski, 2011). Regardless of this progress
and despite the work of many investigators, it is clear that we
have barely scratched the surface in this complex topic. We
anticipate that in the coming years many new targets of AMIwill be identified, and hopefully the promising antibody-based
reagents and vaccines that are currently in various stages of
preclinical and clinical development will lead to licensed prod-
ucts that will transform our approach to fungal diseases.
However, in our view, the greatest challenge facing this field,
and all of immunology, is how to integrate AMI with the other
components of the immune system to produce a coherent
picture of effective and noneffective immune responses that
would be predictive and useful in guiding the design of new
vaccines and immune therapies.ACKNOWLEDGMENTS
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